



23 October 2025

**Trifast plc**  
(the "Company")

**Director/PDMR shareholding**

The following amendment has been made to the 'Director/PDMR shareholding' announcement released on 15 October 2025 at 15:06hrs under RNS No. 5383D.

"Mr Percival has a beneficial interest of 397,274 Ordinary Shares in the Company."

All other details remain unchanged.

The full amended text is shown below.

The Company announces that on 10 October 2025, Mr. Iain Percival, Chief Executive Officer, acquired 5619 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 82.2p which were purchased under the Company's Dividend Re-Investment Plan.

On 14 October 2025, Mr. Clive Watson, Senior Independent Non-Executive Director, acquired 1665 ordinary shares of 5 pence each in the Company ("Ordinary Shares") at a price of 82.32p which were purchased under the Company's Dividend Re-Investment Plan.

Following these transactions, Mr. Percival and Mr. Watson have a beneficial interest of 397,274 and 116,478 Ordinary Shares in the Company respectively.

**Enquiries:**

**Trifast plc**

Christopher Morgan

Company Secretary

Tel: +44 (0) 1825 769696

[www.trifast.com](http://www.trifast.com)

The notifications below are made in accordance with the requirements of the EU Market Abuse Regulation.

1.	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a.	Name	Iain Percival
2.	<b>Reason for the notification</b>	
a.	Position/status	Chief Executive Officer
b.	Initial notification/Amendment	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a.	Name	Trifast plc
b.	LEI	313000AFW15EDM1/20200

D.	LEI	213800WFIVE6RWK3CR22					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each GB0008883927					
b.	Nature of the transaction	Purchase of shares through the Dividend Re-Investment Plan					
c.	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>82.2p</td><td>5619</td></tr></table>	Price(s)	Volume(s)	82.2p	5619	
Price(s)	Volume(s)						
82.2p	5619						
d.	Aggregated information <ul style="list-style-type: none"><li>Aggregated volume</li><li>Price</li></ul>	5619 82.2p					
e.	Date of the transaction	10 October 2025					
f.	Place of the transaction	London Stock Exchange, Main Market (XLON)					

1.	Details of the person discharging managerial responsibilities / person closely associated						
a.	Name	Clive Watson					
2.	Reason for the notification						
a.	Position/status	Independent Non-Executive Director					
b.	Initial notification/Amendment	Initial notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Trifast plc					
b.	LEI	213800WFIVE6RWK3CR22					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each GB0008883927					
b.	Nature of the transaction	Purchase of shares through the Dividend Re-Investment Plan					
c.	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>82.32p</td><td>1665</td></tr></table>	Price(s)	Volume(s)	82.32p	1665	
Price(s)	Volume(s)						
82.32p	1665						
d.	Aggregated information · Aggregated volume · Price	1665 82.32p					
e.	Date of the transaction	14 October 2025					
f.	Place of the transaction	London Stock Exchange, Main Market (XLON)					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHGZMZGVFNGKZM